/

HALO

Halozyme Therapeutics, Inc.Pre-market

111.08+0.66 +0.60%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delayPre-market 113.00 +1.73%

Open

110.19

Prev close

110.42

Day range

109.96112.43

52-week range

61.23116.85

Volume

1.66M0.76×

Mkt cap

12.61B

P/E ttm

32.48

Fwd P/E

10.45

EPS ttm

3.42

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−4.94%

Price Chart

Yahoo Finance · delayed

HALOOct 12, 2026O 110.19H 112.43L 109.96C 111.08+0.66 (+0.60%)Vol 1.66M

SMA 50106.22
SMA 20079.63

1Y change +73.29% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

HALO Halozyme Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.56%
1 month: +3.62%
3 months: +45.95%
6 months: +65.84%
Year to date: +65.05%
1 year: +73.29%

Valuation & ownership

Market cap: 12.61B
Enterprise value: 14.55B
P/E (ttm): 32.48
Forward P/E: 10.45
PEG ratio: —
Price / book: 88.23
Price / sales (ttm): 7.58
EV / EBITDA: 13.85
EPS (ttm): 3.42
EPS (forward): 10.63
Beta (5y monthly): 0.88
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 113.50M
Float: 112.19M
Short % of float: 17.67%
Short ratio (days): 6.48
Held by insiders: 1.08%
Held by institutions: 113.19%
Avg volume (3m): 2.18M
50-day average: 106.22
200-day average: 79.63
52-week change: +73.29%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 55.3
vs 50-day SMA: +4.58%
vs 200-day SMA: +39.49%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 2.79%
Realised vol (20d, ann.): 29.3%
From 52-week high: −4.94%
From 52-week low: +81.41%

ANR

Analyst Consensus

8 analysts

Consensus

Buy

1.67 on a 1 (strong buy) – 5 (sell) scale

Mean target

101.75

−8.40% implied

Low 78.00Median 100.00High 130.00

Recommendation trend

Now7 / 2 / 0
1m ago / 2 /

DES

About Halozyme Therapeutics, Inc.

Yahoo Finance profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 423
Headquarters: San Diego, CA, United States

SEAS

Seasonality · HALO

2007–2026 · monthly returns

Strongest month Nov +8.22%Weakest month Oct −3.62%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	6.6	-3.0	-7.0	-1.5	4.5	17.6	5.5	29.0	3.7	0.6			+65.1%
2025	18.5	4.4	7.9	-3.7	-8.7	-7.2	15.3	22.0	0.3	-11.1	9.5	-5.7	+40.8%
2024	-8.4	17.6	2.2	-6.3	16.2	18.2	5.5	15.5	-10.4	-11.7	-4.7	-0.8	+29.4%
2023	-9.0	-7.3	-20.4	-15.9	0.9	11.2	19.1	-0.9	-10.2	-11.3	14.0	-4.3	−35.0%
2022	-13.9	2.5	12.4	0.1	15.2	-4.3	11.1	-16.7	-2.9	20.9	19.8	-0.6	+41.5%
2021	11.4	-4.9	-7.9	19.8	-17.1	9.7	-9.0	1.6	-3.1	-6.4	-13.6	22.3	−5.9%
2020	7.1	3.1	-8.1	26.0	7.1	10.5	1.4	6.7	-9.4	6.5	39.6	9.2	+140.9%
2019	10.6	6.6	-6.7	0.2	-8.6	16.5	-1.1	-2.8	-6.1	-1.2	26.6	-8.6	+21.2%
2018	-7.8	5.2	-0.4	-3.4	-2.8	-8.3	7.3	1.7	-1.3	-14.5	6.3	-11.4	−27.8%
2017	16.9	11.0	1.1	7.6	-15.4	8.6	-1.1	2.6	33.5	2.1	5.3	8.5	+105.1%
2016	-49.2	-7.6	16.5	11.4	-4.6	-14.2	15.2	-1.4	23.3	-28.6	36.8	-16.3	−43.0%
2015	48.0	5.5	-5.2	4.1	16.7	30.1	3.4	-25.2	-23.1	16.5	13.7	-2.6	+79.6%
2014	4.5	-10.0	-9.8	-41.4	6.0	25.1	-1.4	-2.5	-4.2	5.7	-8.7	9.9	−35.6%
2013	-0.3	-18.5	5.9	4.7	16.9	12.6	7.0	-2.4	32.9	5.5	26.7	1.6	+123.4%
2012	11.0	9.0	10.9	-36.7	-5.4	16.0	1.8	-35.7	30.0	-29.8	17.8	7.7	−29.4%
2011	-15.8	3.6	-2.9	-1.2	1.7	2.5	0.4	-2.0	-9.7	37.3	12.5	0.3	+20.1%
2010	-7.7	0.9	46.1	6.6	-14.0	-4.0	1.8	6.6	0.9	-4.9	-5.3	14.1	+34.9%
2009	3.0	-23.2	23.3	15.8	10.6	-0.1	1.1	5.4	-4.4	-14.8	-9.9	7.5	+4.8%
2008	-22.5	-0.2	15.6	-22.3	4.9	3.9	48.9	-2.6	-5.9	-34.7	-22.5	50.9	−21.2%
2007	-6.2	9.8	-2.8	25.9	0.6	-9.6	-12.9	9.6	-1.4	5.6	-7.6	-16.2	−11.7%

INSD

Insider Activity · HALO

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

325K shares

Sells, 6 months

314.7K shares

Net shares

+10.3K

Net change in insider shares

+0.80%

Date	Insider	Transaction	Shares	Value
Oct 7, 2026	Torley Helen IChief Executive Officer	Sale at price 107.90 - 113.69 per share.	60K	$6.61M
Oct 7, 2026	Torley Helen IChief Executive Officer	Conversion of Exercise of derivative security at price 18.41 per share.	60K	$1.10M
Sep 15, 2026	Posard Matthew LDirector	Sale at price 106.13 - 108.99 per share.	19K	$2.05M
Sep 10, 2026	Torley Helen IChief Executive Officer	Sale at price 107.01 - 108.67 per share.	60K	$6.44M
Sep 10, 2026	Torley Helen IChief Executive Officer	Conversion of Exercise of derivative security at price 18.41 per share.	60K	$1.10M
Aug 31, 2026	Appelhans DannielleDirector	Stock Award(Grant) at price 0.00 per share.	1.2K	—
Aug 18, 2026	Torley Helen IChief Executive Officer	Sale at price 98.96 - 107.76 per share.	60K	$6.28M
Aug 18, 2026	Torley Helen IChief Executive Officer	Conversion of Exercise of derivative security at price 18.41 per share.	60K	$1.10M
Aug 9, 2026	Connaughton Bernadette M.Director	Sale at price 102.80 per share.	1.6K	$167.15K
Jul 7, 2026	Torley Helen IChief Executive Officer	Sale at price 79.28 - 80.19 per share.	1.9K	$153.39K
Jul 7, 2026	Torley Helen IChief Executive Officer	Conversion of Exercise of derivative security at price 12.07 per share.	1.9K	$23.21K
Jun 30, 2026	Connaughton Bernadette M.Director	Sale at price 76.40 - 77.21 per share.	1.6K	$124.65K
Jun 28, 2026	Krishnan Mahesh M.D., MphDirector	Sale at price 75.00 per share.	7.3K	$547.80K
Jun 28, 2026	Krishnan Mahesh M.D., MphDirector	Conversion of Exercise of derivative security at price 38.46 per share.	7.3K	$280.91K
Jun 11, 2026	Snyder Mark HowardOfficer	—	5K	—
Jun 2, 2026	Torley Helen IChief Executive Officer	Sale at price 66.31 - 69.69 per share.	50K	$3.37M
Jun 2, 2026	Torley Helen IChief Executive Officer	Conversion of Exercise of derivative security at price 12.07 per share.	50K	$603.50K
May 31, 2026	Connaughton Bernadette M.Director	Sale at price 66.21 per share.	1.6K	$107.59K
May 12, 2026	Torley Helen IChief Executive Officer	Sale at price 64.63 - 73.12 per share.	50K	$3.43M
May 12, 2026	Torley Helen IChief Executive Officer	Conversion of Exercise of derivative security at price 12.07 per share.	50K	$603.50K

CONG

Congress Trades · HALO

House reports since 2025

Members

1 last bought

Buys

~$8.0K

Sells

~$8.0K

Net

+$0

est. bought − sold

Latest

Mar 9, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	1	1	+$0	Bought Mar 9, 26

Bought and sold by quarter (est.)

House members' HALO trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Mar 9, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Apr 7, 26 (29d)	PDF
Mar 24, 25	Gilbert Cisneros CA31	Self	Sell (part)	$1,001 - $15,000	Apr 7, 25 (14d)	PDF

From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

HALO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

HALO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Halozyme Therapeutics, Inc.

Seasonality · HALO

Insider Activity · HALO

Congress Trades · HALO

Members who traded it

Bought and sold by quarter (est.)

Congress Trades · HALO

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · HALO

Seasonality · HALO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Halozyme Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News